[Kinetic effects of 6% hydroxyethyl starch 200.000/0.6-0.66 in hypervolemic hemodilution].
An open study was carried out in order to examine therapeutic effectivity of repeated administration of 6% hydroxyethyl starch 200.000/0.60-0.66 (HES). 10 patients aged 63 to 77 years with peripheral arterial occlusive disease Stage II b were given 500 ml Elohaest as a hypervolemic hemodilution for 12 days. Fasting levels of hydroxyethyl starch (HES) in serum, hematocrit, and serum-alpha-amylase were measured. During the first 4 treatment days, HES levels and serum-alpha-amylase increased in a significant manner; then it fluctuated towards a plateau without significant differences. The hematocrit decreased significantly from the beginning to the end of therapy. So it was possible to show, that during repeated application with the chosen dosage of 6% HAES 200.000/0.6-0.66 there is no dangerous cumulation of HAES.
Költringer
P
P
Neurologischen Abteilung, Barmherzige Brüder Eggenberg, Graz, Austria.
Langsteger
W
W
Lind
P
P
Klima
G
G
Pierer
G
G
Reisecker
F
F
Eber
O
O
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000628:therapy*; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D001809:Blood Viscosity / Q000187:drug effects* / Q000502:physiology; D001810:Blood Volume / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006400:Hematocrit; D006438:Hemodilution / Q000379:methods*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D007511:Ischemia / Q000097:blood / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008657:Metabolic Clearance Rate / Q000502:physiology; D008875:Middle Aged
D006895:Hydroxyethyl Starch Derivatives
Kinetikeffekte von 6% HAES 200.000/0,6-0,66 bei hypervolämischer Hämodilution.